JP2023532278A5 - - Google Patents

Info

Publication number
JP2023532278A5
JP2023532278A5 JP2022579946A JP2022579946A JP2023532278A5 JP 2023532278 A5 JP2023532278 A5 JP 2023532278A5 JP 2022579946 A JP2022579946 A JP 2022579946A JP 2022579946 A JP2022579946 A JP 2022579946A JP 2023532278 A5 JP2023532278 A5 JP 2023532278A5
Authority
JP
Japan
Prior art keywords
amino acid
sequence
seq
tcr
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532278A (ja
JP7781085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039262 external-priority patent/WO2021263211A2/en
Publication of JP2023532278A publication Critical patent/JP2023532278A/ja
Publication of JP2023532278A5 publication Critical patent/JP2023532278A5/ja
Priority to JP2025136019A priority Critical patent/JP2025166212A/ja
Application granted granted Critical
Publication of JP7781085B2 publication Critical patent/JP7781085B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579946A 2020-06-25 2021-06-25 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 Active JP7781085B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136019A JP2025166212A (ja) 2020-06-25 2025-08-18 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044150P 2020-06-25 2020-06-25
US63/044,150 2020-06-25
PCT/US2021/039262 WO2021263211A2 (en) 2020-06-25 2021-06-25 Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136019A Division JP2025166212A (ja) 2020-06-25 2025-08-18 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法

Publications (3)

Publication Number Publication Date
JP2023532278A JP2023532278A (ja) 2023-07-27
JP2023532278A5 true JP2023532278A5 (cg-RX-API-DMAC7.html) 2023-08-24
JP7781085B2 JP7781085B2 (ja) 2025-12-05

Family

ID=79281973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022579946A Active JP7781085B2 (ja) 2020-06-25 2021-06-25 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法
JP2025136019A Pending JP2025166212A (ja) 2020-06-25 2025-08-18 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136019A Pending JP2025166212A (ja) 2020-06-25 2025-08-18 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法

Country Status (7)

Country Link
US (1) US20230250149A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171587A4 (cg-RX-API-DMAC7.html)
JP (2) JP7781085B2 (cg-RX-API-DMAC7.html)
CN (1) CN116322750A (cg-RX-API-DMAC7.html)
AU (1) AU2021297458B2 (cg-RX-API-DMAC7.html)
CA (1) CA3188143A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021263211A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519675A4 (en) * 2022-05-03 2026-04-08 3T Biosciences Inc T-LYMPHOCYTE TARGET DISCOVERY
WO2023228968A1 (ja) * 2022-05-25 2023-11-30 国立大学法人東海国立大学機構 ポリヌクレオチド
WO2024163292A1 (en) * 2023-01-30 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof
WO2024263821A2 (en) * 2023-06-20 2024-12-26 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
AU2024312524A1 (en) * 2023-06-20 2026-01-22 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
WO2025084880A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2951202T (pt) * 2013-01-29 2020-07-07 Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch Moléculas de ligação de alta avidez que reconhecem mage-a1
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
RU2716716C2 (ru) 2014-10-27 2020-03-16 Фред Хатчинсон Кэнсер Рисёрч Сентер Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
MA44907A (fr) * 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
MX2018008416A (es) * 2016-01-08 2019-11-11 Univ California Polipéptidos heterodímericos condicionalmente activos y métodos para su uso.
AU2017232431A1 (en) * 2016-03-15 2018-09-20 Cancer Research Technology Limited Chimeric antigen receptor
US20210079061A1 (en) 2018-02-26 2021-03-18 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
WO2019241688A1 (en) * 2018-06-14 2019-12-19 Bluebird Bio, Inc. Cd79b chimeric antigen receptors
CN113454110B (zh) * 2018-10-23 2024-07-02 里珍纳龙药品有限公司 Ny-eso-1 t细胞受体和其使用方法

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
US11168150B2 (en) T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
KR102048477B1 (ko) 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
CN108610420B (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
AU2016305697B2 (en) Novel anti-PD-1 antibodies
JP6588534B2 (ja) 抗pd−1のモノクローナル抗体およびその獲得方法
NL2014935B1 (en) T cell receptor like antibodies having fine specificity.
AU2017414149B2 (en) Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
US10618962B2 (en) Anti-CTLA4 antibodies
JP7395471B2 (ja) 改変抗SIRPa抗体及びその使用
US20230076027A1 (en) Hhla2 as a novel inhibitor of human immune system and uses thereof
CA3066779A1 (en) Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
JP2018529327A5 (cg-RX-API-DMAC7.html)
KR20190105112A (ko) 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
CN101541834A (zh) 癌症的预防和/或治疗剂
KR102048476B1 (ko) 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
CN121248790A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
JP2022542559A5 (cg-RX-API-DMAC7.html)
CN121427832A (zh) 细胞
CA3145857A1 (en) Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof
CN108948194A (zh) 一种新的ctla-4单克隆抗体
CN119278213A (zh) 针对ctla-4的抗体及其使用方法
JP2024105603A (ja) CARライブラリおよびscFvの製造方法
EP3875478A1 (en) Novel non-immunogenic chimeric antigen receptors and uses thereof